Literature DB >> 27067659

[Testosterone therapy].

T Diemer1, A Hauptmann2, F M E Wagenlehner2.   

Abstract

Hormone replacement therapy with testosterone has become well-established over the course of time. The initial substantial concerns with respect to complications and potential adverse events, particularly in older patients, were proven to be unfounded over time. Testosterone therapy has therefore gradually become a regular treatment modality in urological practice. It has also been shown to represent a valuable tool as supportive treatment for patients with erectile dysfunction and hypogonadism. A variety of testosterone preparations are available for treatment. Recent pharmaceutical developments have greatly improved the practicability and ease of administration for patients. Several guidelines have been developed that provide clearly formulated standards and instructions for indications, contraindications, application, risk factors and monitoring of testosterone therapy. Adverse events affecting the cardiovascular system and especially diseases of the prostate gland are of great importance, thus making the urologist the primary partner in the treatment of patients with testosterone deficiency.

Entities:  

Keywords:  Erectile dysfunction; Hormone replacement therapy; Hypogonadism; Late-onset hypogonadism; Testosterone

Mesh:

Substances:

Year:  2016        PMID: 27067659     DOI: 10.1007/s00120-016-0072-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  14 in total

Review 1.  Sexuality of the elderly.

Authors:  W Weidner; J Altwein; E Hauck; M Beutel; E Brähler
Journal:  Urol Int       Date:  2001       Impact factor: 2.089

2.  Identification of late-onset hypogonadism in middle-aged and elderly men.

Authors:  Frederick C W Wu; Abdelouahid Tajar; Jennifer M Beynon; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe F Casanueva; Gianni Forti; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Michael E J Lean; Neil Pendleton; Margus Punab; Steven Boonen; Dirk Vanderschueren; Fernand Labrie; Ilpo T Huhtaniemi
Journal:  N Engl J Med       Date:  2010-06-16       Impact factor: 91.245

3.  Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations.

Authors:  E Nieschlag; R Swerdloff; H M Behre; L J Gooren; J M Kaufman; J-J Legros; B Lunenfeld; J E Morley; C Schulman; C Wang; W Weidner; F C W Wu
Journal:  Int J Androl       Date:  2005-06

Review 4.  ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males.

Authors:  C Wang; E Nieschlag; R Swerdloff; H M Behre; W J Hellstrom; L J Gooren; J M Kaufman; J-J Legros; B Lunenfeld; A Morales; J E Morley; C Schulman; I M Thompson; W Weidner; F C W Wu
Journal:  Int J Impot Res       Date:  2008-10-16       Impact factor: 2.896

5.  Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update.

Authors:  Bruno Lunenfeld; George Mskhalaya; Svetlana Kalinchenko; Yulia Tishova
Journal:  Aging Male       Date:  2013-11-04       Impact factor: 5.892

6.  Correlations between hormones, physical, and affective parameters in aging urologic outpatients.

Authors:  M E Beutel; J Wiltink; E W Hauck; D Auch; H M Behre; E Brähler; W Weidner
Journal:  Eur Urol       Date:  2005-03-09       Impact factor: 20.096

Review 7.  Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction.

Authors:  Abdulmaged M Traish; Irwin Goldstein; Noel N Kim
Journal:  Eur Urol       Date:  2007-02-20       Impact factor: 20.096

8.  Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study.

Authors:  Henry A Feldman; Christopher Longcope; Carol A Derby; Catherine B Johannes; Andre B Araujo; Andrea D Coviello; William J Bremner; John B McKinlay
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

9.  An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome.

Authors:  Farid Saad; Louis Gooren; Ahmad Haider; Aksam Yassin
Journal:  Arch Androl       Date:  2007 Nov-Dec

Review 10.  Testosterone and erectile dysfunction.

Authors:  Aksam A Yassin; Farid Saad
Journal:  J Androl       Date:  2008-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.